Follow us on social

Shutterstock_1860838507-scaled

Vaccine vote was early test for Biden’s new ‘global leadership’ and he failed

The administration's stance on a patent waiver puts Big Pharma profits before human life — and sound foreign policy.

Analysis | Washington Politics

Just last week the Biden administration faced, and failed, a largely ignored test for its foreign policy. Joined by the United Kingdom and the European Union, the United States once again blocked a measure at the World Trade Organization that would temporarily waive patent rules to promote greater availability of vaccines and treatments to aid in the fight against COVID-19 worldwide.

If adopted, the proposal would have permitted generic and other pharmaceutical companies to begin manufacturing already-effective vaccines that could slow and halt the spread of COVID, prevent dangerous new variants, and likely save hundreds of thousands of lives, especially in the Global South. The measure was introduced by India and South Africa last October, and is supported by nearly 100 low and middle income countries, NGOs like Amnesty International and Medecins Sans Frontieres, and some U.S. lawmakers, most notably Senator Bernie Sanders.

The need for expanding vaccine access is clear. Over half of the anticipated vaccine supply for 2021 has already been purchased by a handful of wealthy nations, and at present many poor countries are not on track for full immunization until 2023 or 2024

Addressing this is hardly a question of altruism for the United States. The WHO estimates that vaccine inequality could cost the global economy $9.2 trillion, and the continued spread of COVID globally would expose the U.S. to the risk of renewed outbreaks.

Response to the decision in the United States has been mute. Alex Pareene notes in The New Republic that media coverage has focused instead on the notion that the United States should donate some of the extra doses it has already purchased to poorer nations — a proposal that would be understandably unpopular with the millions of Americans still waiting to be vaccinated themselves.

In an article that provides a case study in the derangement of U.S. foreign policy discourse, the Washington Post primarily characterized the demand to share vaccines worldwide as driven by the need to counter China and Russia’s “aggressive vaccine diplomacy.” The article quotes experts suggesting, among other things, that these countries are “striking in our own backyard” by providing vaccines to Latin America.

The Biden administration has likewise focused its international vaccine distribution efforts on countering Russia and especially China. But the commitments it has made so far are too narrow and will take years to be fully delivered. Just days after blocking the waiver, the Biden administration pledged in a joint statement with the leaders of India, Australia, and Japan, to facilitate the production and distribution of 1 billion vaccines across Asia — but this target would fail to fulfill the needs of India alone, and would not be met until the end of 2022.

Likewise, the WHO-backed COVAX initiative, which the Biden administration joined in January, only aims to provide enough vaccines for 20 percent of the developing world’s population by the end of 2021.

The relative lack of attention given to the patent waiver issue is unfortunate considering that it presents a feasible way to make vaccines available across the Global South without any cost to the average U.S. citizen — and is supported by almost 70 percent of U.S. adults, according to a YouGov poll published just last week.

The reason for the Biden administration’s (and the EU and UK’s) resistance is, naturally, pharmaceutical company profits — or, in the words of Western governments, “incentives for innovation.” (PHrMA, the leading industry lobby group which last year spent over $530 million on lobbying and political donations, has vocally opposed a waiver.)

Of course, profits do provide incentives for pharmaceutical companies to produce effective vaccines, and, in the case of COVID, to do so with unprecedented speed. But these companies already are set to receive fantastic profits from their COVID vaccines — and, because they would retain an advantage in manufacturing their vaccines even without exclusive production rights, they stand to make a great deal more. 

Furthermore, if they deem it necessary, Western governments could even provide additional compensation for profits lost to a waiver. The notion, then, that a waiver in this instance would dissuade companies like Pfizer and Moderna from producing future vaccines is simply not credible.

In short, the Biden administration has been offered a relatively easy moral and strategic win that could both enhance U.S. national security and provide a significant soft-power reward. But it has declined this chance in defense of some amount of Big Pharma’s vaccine profits — a curious choice for an administration that has promised to pursue a “foreign policy for the middle class.” 

Members of the U.S. foreign policy establishment routinely fret about growing Chinese influence in Latin America, Africa, Asia, and the Middle East. Yet when given the chance to show a minimum level of interest in saving the lives of people there, this same crowd quietly rejects it. There is an imperative, an existential demand, that the United States maintain its “global leadership” — but not at the expense of lower profits for Pfizer and Moderna.

The first year of the COVID-19 pandemic revealed a deep hole in the American state’s capacity for domestic governance. The patent waiver episode reveals a problem of similar scale for American statecraft — that it is hobbled by the U.S. government’s fealty to corporate interests.

Washington spends billions of dollars on weapons it doesn’t really need in order to create or maintain jobs and to line the pockets of defense contractors (that are also profligate political donors). This helps keep U.S. statecraft militarized, encourages the continuous inflation of foreign threats in order to justify ever-higher Pentagon budgets, and crowds out spending that could be far more useful in the long run — such as a green industrial policy, or larger investments in public health and infrastructure. Military spending is favored even though it is relatively ineffective at creating jobs and stimulating economic growth, compared to other types of spending. 

This is why hopes that intensified competition with China might unify and revitalize the United States — beyond the inherent dangers of overhyping a foreign threat to achieve national unity — are unlikely to be fulfilled. With the interests and inertia that presently dominate the U.S. state, American investment in such a competition will likely be massively skewed towards military spending and other inefficient and ultimately destructive corporate handouts.

We already know what this looks like. As Mark Leon Goldberg points out on Twitter, the United States has spent $1.6 trillion on the F-35, a plane that might decapitate its pilot on ejection, compared to China’s $1.3 trillion in total spending on its dreaded “Belt and Road Initiative.”.

The United States is facing a world replete with threats, like climate change and pandemics, that are less amenable to military spending or purely profit-oriented solutions. To meet these challenges, U.S. leaders will have to learn to recognize when national interests seriously diverge from the interests of U.S. corporations — and be willing to confront the latter.

A country incapable of doing this can hardly be expected to successfully engage in a globe-spanning “strategic competition.” More importantly, it cannot be expected to ensure even a minimally humane future for its residents or for the world more broadly.

To change this will require a serious shift in U.S. foreign policy thinking and in the distribution of power in Washington. Vocal and serious opposition to the Biden administration’s indefensible approach to a patent waiver is a good place to start.


(shutterstock/ Dimitris Barletis)
Analysis | Washington Politics
Kim Jong Un
Top photo credit: North Korean leader Kim Jong Un visits the construction site of the Ragwon County Offshore Farm, North Korea July 13, 2025. KCNA via REUTERS

Kim Jong Un is nuking up and playing hard to get

Asia-Pacific

President Donald Trump’s second term has so far been a series of “shock and awe” campaigns both at home and abroad. But so far has left North Korea untouched even as it arms for the future.

The president dramatically broke with precedent during his first term, holding two summits as well as a brief meeting at the Demilitarized Zone with the North’s Supreme Leader Kim Jong-un. Unfortunately, engagement crashed and burned in Hanoi. The DPRK then pulled back, essentially severing contact with both the U.S. and South Korea.

keep readingShow less
Why new CENTCOM chief Brad Cooper is as wrong as the old one
Top photo credit: U.S. Navy Vice Admiral Brad Cooper speaks to guests at the IISS Manama Dialogue in Manama, Bahrain, November 17, 2023. REUTERS/Hamad I Mohammed

Why new CENTCOM chief Brad Cooper is as wrong as the old one

Middle East

If accounts of President Donald Trump’s decision to strike Iranian nuclear facilities this past month are to be believed, the president’s initial impulse to stay out of the Israel-Iran conflict failed to survive the prodding of hawkish advisers, chiefly U.S. Central Command (CENTCOM) chief Michael Kurilla.

With Kurilla, an Iran hawk and staunch ally of both the Israeli government and erstwhile national security adviser Mike Waltz, set to leave office this summer, advocates of a more restrained foreign policy may understandably feel like they are out of the woods.

keep readingShow less
Putin Trump
Top photo credit: Vladimir Putin (Office of the President of the Russian Federation) and Donald Trump (US Southern Command photo)

How Trump's 50-day deadline threat against Putin will backfire

Europe

In the first six months of his second term, President Donald Trump has demonstrated his love for three things: deals, tariffs, and ultimatums.

He got to combine these passions during his Oval Office meeting with NATO Secretary General Mark Rutte on Monday. Only moments after the two leaders announced a new plan to get military aid to Ukraine, Trump issued an ominous 50-day deadline for Russian President Vladimir Putin to agree to a ceasefire. “We're going to be doing secondary tariffs if we don't have a deal within 50 days,” Trump told the assembled reporters.

keep readingShow less

LATEST

QIOSK

Newsletter

Subscribe now to our weekly round-up and don't miss a beat with your favorite RS contributors and reporters, as well as staff analysis, opinion, and news promoting a positive, non-partisan vision of U.S. foreign policy.